Nausea is the most common, with relative risk ratios of 2.69 at 4 mg, 4.27 at 8 mg, and 4.00 at 12 mg compared to placebo
Interesting Finding: Reduced Alcohol Cravings Interestingly, recent research has found that GLP-1 medications may actually reduce alcohol cravings and consumption in some individuals: Studies have shown that both semaglutide (GLP-1 agonist) and tirzepatide (GLP-1/GIP combination) appear to effectively reduce alcohol consumption in individuals with obesity
Rabbit experimental wounds showed improved wound contraction, enhanced granular tissue formation, increased antioxidant enzyme activity, and stimulated blood vessel growth, with enhanced effects when combined with helium-neon laser therapy
Observational reports from practitioners combining these therapies are limited and not yet systematized in peer-reviewed literature
Free form tyrosine doesnt dissolve easily in water, meaning its not very soluble
However, nausea onset with tirzepatide can be slightly more pronounced during early weeks, though long-term tolerability appears similar